46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

60 trials found

diseases per page:

Showing 1 to 10 of 60 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05080218 (ClinicalTrials.gov)	October 2021	6/10/2021	COVID-19 VaccinE Response in Rheumatology Patients	The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary I ...	Rheumatoid Arthritis;Psoriatic Arthritis;Spondylarthritis	Drug: Upadacitinib;Drug: Abatacept;Drug: Secukinumab;Drug: Tofacitinib;Drug: TNF Inhibitor;Drug: Can ...	Jeffrey Curtis	University of Alabama at Birmingham;University of Nebraska;University of Pennsylvania;AbbVie;Bristol ...	Not yet recruiting	18 Years	85 Years	All	1000	Phase 4	United States
2	NCT04798287 (ClinicalTrials.gov)	March 10, 2021	11/3/2021	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: TNF Inhibitor	Brigham and Women's Hospital	NULL	Active, not recruiting	18 Years	N/A	All	105711		United States
3	NCT04772248 (ClinicalTrials.gov)	February 22, 2021	23/2/2021	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular E ...	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular E ...	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: TNF Inhibitor	Brigham and Women's Hospital	NULL	Completed	18 Years	N/A	All	105711		United States
4	NCT04086745 (ClinicalTrials.gov)	February 14, 2020	10/9/2019	A Study of Baricitinib in Participants With Rheumatoid Arthritis	A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthr ...	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Recruiting	18 Years	N/A	All	1300	Phase 4	United States
5	NCT03915964 (ClinicalTrials.gov)	April 25, 2019	12/4/2019	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis	A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rh ...	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Active, not recruiting	18 Years	N/A	All	2600	Phase 4	United States;Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;L ...
6	EUCTR2015-002887-17-FR (EUCTR)	19/06/2017	16/02/2016	Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design S ...	Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate With or Without ...	Product Name: BTK Inhibitor Product Code: BMS-986142 INN or Proposed INN: BTK Inhibitor Product Name: B ...	Bristol-Myers Squibb International Corporation	NULL	Not Recruiting			Female: yes Male: yes	610	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Taiwan;Spain;Austria;Russian Federation;Israel;Italy;France;Mexico;Canada;Argentina;Po ...
7	NCT02862574 (ClinicalTrials.gov)	December 15, 2016	8/8/2016	Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adu ...	Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibi ...	Rheumatoid Arthritis	Drug: Andecaliximab;Drug: Placebo;Drug: Methotrexate;Drug: TNF Inhibitor	Gilead Sciences	NULL	Terminated	18 Years	80 Years	All	15	Phase 2	United States;Australia;Hungary;Taiwan
8	JPRN-JapicCTI-163317	28/7/2016	13/07/2016	Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design S ...	Rheumatoid Arthritis	Intervention name : BMS-986142 INN of the intervention : - Dosage And administration of the interventi ...	Bristol-Myers Squibb K.K.	NULL	complete	18	120	BOTH	408	Phase 2	Japan, Asia except Japan, North America, South America, Europe, Oceania
9	EUCTR2015-002887-17-BE (EUCTR)	07/06/2016	16/02/2016	Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design S ...	Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate With or Without ...	Product Name: BTK Inhibitor Product Code: BMS-986142 INN or Proposed INN: BTK Inhibitor Product Name: B ...	Bristol-Myers Squibb International Corporation	NULL	Not Recruiting			Female: yes Male: yes	610	Phase 2	United States;Taiwan;Spain;Austria;Russian Federation;Israel;Italy;France;Mexico;Canada;Argentina;Po ...
10	EUCTR2015-002887-17-NL (EUCTR)	20/04/2016	22/02/2016	Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design S ...	Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate With or Without ...	Product Name: BTK Inhibitor Product Code: BMS-986142 INN or Proposed INN: BTK Inhibitor Product Name: B ...	Bristol-Myers Squibb International Corporation	NULL	Not Recruiting			Female: yes Male: yes	610	Phase 2	United States;Taiwan;Spain;Austria;Russian Federation;Israel;Italy;France;Mexico;Canada;Argentina;Po ...

First Previous1 2 3 4 5 6Next Last